ARKG241129C25500
- 0.13
- -0.22-62.86%
ARK Genomic Revolution ETF Newsroom
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Recursion Pharmaceuticals Analyst Ratings
Trump Media Saw the Largest Increase in Short Interest in October
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $52
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Analyst Ratings
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Expectations For Natera's Future
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript Summary
Veracyte Analyst Ratings
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Twist Bioscience Expects Q1 2025 Sales Of ~$87M Vs. Consensus Of $84.473M
Twist Bioscience GAAP EPS of -$0.59 Beats by $0.11, Revenue of $84.71M Beats by $2.05M
Earnings Scheduled For November 18, 2024